Clinical trial
Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old…
NCT00258895 · Sanofi Pasteur, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00258895 |
|---|---|
| Title | Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL® |
| Official title | Safety and Immunogenicity of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With DAPTACEL® or Pentacel® |
| Lead sponsor | Sanofi Pasteur, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diphtheria, Tetanus, Pertussis |
| Intervention type | Biological |
| Interventions | DAPTACEL®: DTaP |
| Enrollment | 649 |
| Start date | Mar 1, 2005 |
| Primary completion | Dec 1, 2006 |
| Completion | Apr 1, 2007 |
| First posted | Nov 28, 2005 |
| Last update posted | Apr 14, 2016 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: